STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...

In a recent study published in JAMA, researchers evaluated the positivity rate of cutaneous phosphorylated alpha-synuclein protein (P-SYN) deposition among individuals with dementia with Lewy body ...

Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...

Promising new research shows Alterity’s novel brain imaging tool could play a key role in diagnosing and tracking Multiple System Atrophy. Quality peer-reviewed publication highlights use of ...

Multiple system atrophy (MSA) is a sporadic and rare neurodegenerative movement disorder with an estimated annual incidence of 0.6 per 100,000 (ORPHA102) The clinical presentation is highly variable, ...